Cite

HARVARD Citation

    Wildsmith, S. et al. (n.d.). 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC). Journal for immunotherapy of cancer. pp. A163-A164. [Online]. 
  
Back to record